PUS4_TRUB1 inhibitors are a class of chemical compounds that focus on the inhibition of a specific enzyme known as Pseudouridine Synthase 4 (PUS4) in the species Trichomonas brucei (denoted as TRUB1). Pseudouridine synthases are enzymes that catalyze the isomerization of uridine to pseudouridine in RNA molecules. Pseudouridylation is a post-transcriptional modification that alters the stability and function of RNA, including tRNA and rRNA, by enhancing the molecules' structural rigidity and contributing to the fidelity of protein synthesis. The PUS4 enzyme, in particular, plays a vital role in the biogenesis of RNA by modifying specific uridine residues, which are critical for maintaining the proper structure and function of RNA. Inhibitors targeting PUS4_TRUB1 are designed to bind to this enzyme and block its activity, thereby affecting the modification process of RNA molecules within the organism.
The design and development of these inhibitors are rooted in the understanding of the enzyme's structure and the biochemistry of the pseudouridylation process. By interfering with PUS4_TRUB1 activity, these inhibitors are able to modulate the RNA maturation process, with a variety of downstream effects on cellular functions. The inhibitors must have high specificity for the PUS4 enzyme to ensure that they do not inadvertently affect similar enzymes in off-target species. The specificity is achieved through the careful design of the inhibitors' molecular structures, which often involves mimicking the natural substrates of the enzyme or binding to unique active site residues. The chemical composition of PUS4_TRUB1 inhibitors typically includes moieties that allow for the tight and specific binding to the enzyme, with the aim of maximizing the inhibition while reducing non-specific interactions. Research in this domain focuses on elucidating the precise mechanisms by which these inhibitors affect the enzyme's activity and how they interact with the enzyme's active site, often using techniques such as X-ray crystallography, computational modeling, and biochemical assays.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits the mTOR pathway, which is involved in protein synthesis and cell proliferation. Its inhibition could reduce the translation and activity of PUS4_TRUB1 as this protein may be synthesized as part of cellular growth and response to mTOR signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks the PI3K/AKT signaling pathway. The PI3K/AKT pathway is upstream of mTOR. By inhibiting this pathway, LY294002 could indirectly decrease the synthesis and function of PUS4_TRUB1 involved in cellular growth processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway, which is vital for cell cycle progression and differentiation. By impeding this pathway, PD98059 may indirectly affect the function of PUS4_TRUB1 if it is involved in these cellular processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that acts similarly to LY294002 and can lead to reduced activity of downstream proteins like PUS4_TRUB1 by inhibiting the PI3K/AKT/mTOR pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can disrupt inflammatory responses and cytokine production. If PUS4_TRUB1 is involved in these responses, inhibiting p38 MAPK can indirectly decrease its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, a kinase involved in stress responses. Inhibition of JNK signaling could lead to decreased function of PUS4_TRUB1 if it plays a role in responding to cellular stress. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits AKT, which is part of the PI3K/AKT/mTOR pathway. It may lead to reduced activity of PUS4_TRUB1 by inhibiting processes that are dependent on this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. It could indirectly lower the activity of PUS4_TRUB1 by inhibiting signaling required for its function. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib inhibits the EGFR tyrosine kinase, which could impact PUS4_TRUB1 activity if it is associated with EGFR signaling pathways that regulate cell proliferation and survival. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib also targets the EGFR pathway, and could indirectly affect PUS4_TRUB1 by inhibiting downstream signaling processes that may involve this protein. | ||||||